Title IV-D Divestiture + Medicare Advantage Appeals Loss to C2C
Per BST III paper protocol, the audit recorded transparent falsifications of two sub-claims of the original Maximus monopoly thesis. Both are documented openly rather than buried.
Falsification #1 — Title IV-D Child Support Enforcement (December 2025 / Q1 FY2026): Maximus completed a full divestiture of its U.S. child support business, recording a $9 million gain and removing $25 million from forward revenue guidance. The original thesis explicitly posited that Maximus controlled the Title IV-D enforcement substrate. As of Q1 2026, Maximus's market share in this category is exactly 0%. The sub-thesis is empirically null.
Falsification #2 — Medicare Advantage Adverse-Determination Appeals (April-May 2026): CMS announced that C2C Innovative Solutions won the contract for reviewing and processing appeals of Medicare Advantage adverse organization determinations and reconsiderations, REPLACING Maximus.
Engine Context: this is the 4th consecutive deep-research audit (after May 6 COVID Wealth Transfer, May 7 MV Hondius, May 8 morning Boring Company) where the original H1 monopoly/single-point-of-control thesis is at least partially falsified. The pre-registration discipline is the active engine norm.
Also in The Population-Facing Federal Services Substrate